Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 13/20 | 0.41 |
| ▸ | GPR183 | P32249 | 1/20 | 0.41 |
| ▸ | CYP4F2 | P78329 | 5/20 | 0.39 |
| ▸ | CYP4A11 | Q02928 | 5/20 | 0.39 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2879305 | 0.89 | GPR119 (0.47) | GPR119GPR183CYP4F2CYP4A11SLC6A9 | |
| SCHEMBL3987252 | 0.84 | GPR119 (0.47) | GPR119GPR183CYP4F2CYP4A11SLC6A9 | |
| SCHEMBL383893 | 0.81 | GPR119 (0.48) | GPR119GPR183CYP4F2CYP4A11SLC6A9 | |
| SCHEMBL384664 | 0.81 | GPR119 (0.47) | GPR119GPR183CYP4F2CYP4A11SLC6A9 | |
| SCHEMBL387662 | 0.79 | GPR119 (0.62) | GPR119 | |
| SCHEMBL384750 | 0.79 | GPR119 (0.61) | GPR119 | |
| SCHEMBL2881163 | 0.78 | GPR119 (0.52) | GPR119GPR183CYP4F2CYP4A11 | |
| SCHEMBL12660703 | 0.78 | KDM1A (0.46) | GPR119GPR183CYP4F2CYP4A11 | |
| SCHEMBL388642 | 0.73 | GPR119 (0.54) | GPR119GPR183CYP4F2CYP4A11SLC6A9 | |
| SCHEMBL387534 | 0.73 | GPR119 (0.77) | GPR119GPR183 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077812-A1 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | FANG JING (US) | 2012-03-29 | — | — | US | disclosed |
| US-8101634-B2 | Bicyclic compounds and use as antidiabetics | GLAXOSMITHKLINE LLC (US) | 2012-01-24 | — | — | US | disclosed |
| EP-2325182-A1 | Bicyclic compounds and use as antidiabetics | Glaxosmithkline LLC (US) | 2011-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077812-A1 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | GPR119, GOT2, PC | GPR119 1/4885GPR183 1491/4885CYP4F2 329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.